Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study
- 1 October 2003
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 1 (10), 2243-2244
- https://doi.org/10.1046/j.1538-7836.2003.00398.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidenceThrombosis and Haemostasis, 2003
- Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of EuropeArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Patients with Coronary Artery Disease Investigated by AngiographyThrombosis and Haemostasis, 2002
- Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study.International Journal of Epidemiology, 2001
- Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic PathwayArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Plasma TAFI Antigen Variations in Healthy SubjectsThrombosis and Haemostasis, 2000
- Plasma Procarboxypeptidase U in Men with Symptomatic Coronary Artery DiseaseThrombosis and Haemostasis, 2000
- The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. Prospective Epidemiological Study of Myocardial InfarctionQJM: An International Journal of Medicine, 1998